December 17, 1999
Death of Research Subject Prompts Debate About Oversight of Gene-Therapy Trials
Scientists, bioethicists, and industry representatives last week debated measures to intensify government oversight of gene-therapy experiments following the death of a teenager enrolled in a clinical trial at the University of Pennsylvania.
The safety of the experiments has come under close scrutiny since 18-year-old Jesse Gelsinger died in September, the first fatality attributed directly to gene therapy. The technique aims to give patients new genes to treat diseases and inherited
This content is only for subscribers. You can gain access by purchasing a:
Print Subscription
Digital Subscription
Already have an account? Log In Now.
-
The Chronicle Review
-
Government
-
Advice
